You have accessJournal of UrologyProstate Cancer: Staging I1 Apr 2015MP53-02 IS CLINICAL STAGE T2C PROSTATE CANCER INTERMEDIATE OR HIGH-RISK DISEASE? Zachary Klaassen, Abhay A. Singh, Lauren E. Howard, Zhaoyong Feng, Bruce Trock, Martha K. Terris, William J. Aronson, Matthew R. Cooperberg, Christopher L. Amling, Christopher J. Kane, Alan Partin, Misop Han, and Stephen J. Freedland Zachary KlaassenZachary Klaassen More articles by this author , Abhay A. SinghAbhay A. Singh More articles by this author , Lauren E. HowardLauren E. Howard More articles by this author , Zhaoyong FengZhaoyong Feng More articles by this author , Bruce TrockBruce Trock More articles by this author , Martha K. TerrisMartha K. Terris More articles by this author , William J. AronsonWilliam J. Aronson More articles by this author , Matthew R. CooperbergMatthew R. Cooperberg More articles by this author , Christopher L. AmlingChristopher L. Amling More articles by this author , Christopher J. KaneChristopher J. Kane More articles by this author , Alan PartinAlan Partin More articles by this author , Misop HanMisop Han More articles by this author , and Stephen J. FreedlandStephen J. Freedland More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.1696AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Clinical stage T2c (cT2c) is an indeterminate factor in the algorithm for prostate cancer (PC) risk stratification. According to D'Amico risk grouping and AUA guidelines, cT2c is high-risk, whereas NCCN and EAU classify cT2c as intermediate-risk. The objective of the study was to assess whether cT2c tumors, without other associated high-risk factors (cT2c not otherwise specified (cT2c-nos)), behave as intermediate or high-risk by analyzing biochemical recurrence (BCR) after radical prostatectomy (RP). METHODS We retrospectively analyzed 2,759 men from the Shared Equal Access Regional Cancer Hospital (SEARCH) database, and 12,900 men from Johns Hopkins Hospital (JHH) from 1988-2011 and 1982-2012, respectively. Comparisons in time to BCR between cT2c-nos and intermediate-risk, and high-risk patients were performed using log-rank test and Cox proportional analyses. RESULTS A total of 99 men (4%) from SEARCH and 202 (2%) from JHH were cT2c-nos. Patients with cT2c-nos had similar BCR risk as intermediate-risk (SEARCH p=0.27; JHH p=0.23), but significantly lower BCR risk vs. high-risk men (SEARCH p<0.001; JHH p<0.001). When specifically compared to intermediate and high-risk patients, and after adjusting for year and center, cT2c-nos patients had outcomes comparable to intermediate-risk (SEARCH p=0.44; JHH p=0.53), but significantly better than high-risk patients (SEARCH p=0.001; JHH p<0.001). CONCLUSIONS BCR risk for patients with cT2c disease without other high-risk features was comparable to men with intermediate-risk and significantly better than men with high-risk PC. These findings suggest men with cT2c PC should be offered treatment options for intermediate-risk PC. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e635 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Zachary Klaassen More articles by this author Abhay A. Singh More articles by this author Lauren E. Howard More articles by this author Zhaoyong Feng More articles by this author Bruce Trock More articles by this author Martha K. Terris More articles by this author William J. Aronson More articles by this author Matthew R. Cooperberg More articles by this author Christopher L. Amling More articles by this author Christopher J. Kane More articles by this author Alan Partin More articles by this author Misop Han More articles by this author Stephen J. Freedland More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...